Terms: = Ovarian cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Clinical Outcome
3 results:
1. Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
Pang Y; Hou X; Yang C; Liu Y; Jiang G
Mol Cancer; 2018 May; 17(1):91. PubMed ID: 29769134
[TBL] [Abstract] [Full Text] [Related]
2. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
[TBL] [Abstract] [Full Text] [Related]
3. Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival.
Wong TF; Yoshinaga K; Monma Y; Ito K; Niikura H; Nagase S; Yamamoto M; Yaegashi N
Int J Gynecol Cancer; 2011 Nov; 21(8):1428-35. PubMed ID: 21897267
[TBL] [Abstract] [Full Text] [Related]